Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMGL NASDAQ:DCGO NASDAQ:SERA NASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMGLBasel Medical Group$2.06+2.0%$2.64$0.91▼$9.40$37.28MN/A6.71 million shs234,630 shsDCGODocGo$1.40+5.3%$1.50$1.23▼$5.68$135.64M0.96487,678 shs374,029 shsSERASera Prognostics$2.59-4.1%$2.34$1.37▼$9.13$101.72M0.99121,293 shs95,513 shsXGNExagen$8.85+2.5%$7.24$1.78▼$9.10$189.89M1.61442,268 shs172,901 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMGLBasel Medical Group+1.98%-8.04%+19.77%-57.08%+205,999,900.00%DCGODocGo+5.26%-6.04%-11.67%-40.17%-56.92%SERASera Prognostics-4.07%-17.52%+3.81%+2.78%-68.10%XGNExagen+2.55%+19.76%+31.40%+37.85%+333.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMGLBasel Medical GroupN/AN/AN/AN/AN/AN/AN/AN/ADCGODocGo2.9239 of 5 stars3.33.00.00.03.22.50.6SERASera Prognostics0.5272 of 5 stars0.02.00.00.02.02.50.0XGNExagen4.5446 of 5 stars4.52.00.04.52.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMGLBasel Medical Group 0.00N/AN/AN/ADCGODocGo 2.50Moderate Buy$3.56154.29% UpsideSERASera Prognostics 0.00N/AN/AN/AXGNExagen 3.00Buy$11.2527.12% UpsideCurrent Analyst Ratings BreakdownLatest BMGL, XGN, DCGO, and SERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.007/30/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $11.007/30/2025XGNExagenKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Weight ➝ Overweight$12.007/23/2025XGNExagenCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.005/15/2025XGNExagenUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.005/13/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/12/2025DCGODocGoCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$5.00 ➝ $1.455/9/2025DCGODocGoNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.005/9/2025DCGODocGoBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/7/2025XGNExagenBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMGLBasel Medical Group$10.00M3.80N/AN/AN/A∞DCGODocGo$520.50M0.27$0.44 per share3.15$3.09 per share0.45SERASera Prognostics$80K1,219.57N/AN/A$1.40 per share1.85XGNExagen$55.64M3.50N/AN/A$0.54 per share16.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMGLBasel Medical GroupN/AN/A0.00∞N/AN/AN/AN/AN/ADCGODocGo$19.99M-$0.02N/A17.50N/A-0.12%2.52%1.70%8/7/2025 (Estimated)SERASera Prognostics-$32.90M-$0.94N/AN/AN/A-28,685.22%-51.35%-37.21%8/6/2025 (Estimated)XGNExagen-$15.11M-$0.89N/AN/AN/A-28.85%-130.38%-34.69%N/ALatest BMGL, XGN, DCGO, and SERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DCGODocGo-$0.06N/AN/AN/A$77.58 millionN/A8/6/2025Q2 2025SERASera Prognostics-$0.21N/AN/AN/A$0.05 millionN/A7/29/2025Q2 2025XGNExagen-$0.18-$0.18N/A-$0.21$16.25 million$17.20 million5/14/2025Q1 2025SERASera Prognostics-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million5/12/2025Q1 2025XGNExagen-$0.20-$0.20N/A-$0.20$14.55 million$15.50 million5/8/2025Q1 2025DCGODocGo-$0.01-$0.09-$0.08-$0.09$104.25 million$96.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMGLBasel Medical GroupN/AN/AN/AN/AN/ADCGODocGoN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMGLBasel Medical GroupN/AN/AN/ADCGODocGoN/A2.442.44SERASera PrognosticsN/A2.022.02XGNExagen1.064.954.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMGLBasel Medical GroupN/ADCGODocGo56.44%SERASera Prognostics54.64%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipBMGLBasel Medical GroupN/ADCGODocGo2.70%SERASera Prognostics15.80%XGNExagen12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMGLBasel Medical Group3618.46 millionN/AN/ADCGODocGo4,407101.98 million99.23 millionOptionableSERASera Prognostics12037.67 million31.72 millionOptionableXGNExagen22022.00 million19.23 millionOptionableBMGL, XGN, DCGO, and SERA HeadlinesRecent News About These CompaniesExagen Inc. (NASDAQ:XGN) Short Interest Up 144.8% in JulyAugust 4 at 2:33 AM | marketbeat.comBTIG Sticks to Their Buy Rating for Exagen (XGN)August 2 at 10:48 PM | theglobeandmail.comFY2026 EPS Estimates for Exagen Cut by Cantor FitzgeraldAugust 2 at 7:25 AM | marketbeat.comWilliam Blair Has Negative Outlook of Exagen FY2025 EarningsAugust 2 at 6:23 AM | marketbeat.comWhat is KeyCorp's Forecast for Exagen Q3 Earnings?August 2 at 5:35 AM | marketbeat.comFY2025 Earnings Forecast for Exagen Issued By William BlairAugust 2 at 2:49 AM | americanbankingnews.comKeyCorp Predicts Exagen's Q3 Earnings (NASDAQ:XGN)August 2 at 2:25 AM | americanbankingnews.comExagen (XGN) Receives a Buy from Craig-HallumAugust 1, 2025 | theglobeandmail.comFY2026 Earnings Forecast for Exagen Issued By KeyCorpAugust 1, 2025 | marketbeat.comExagen Inc. Reports Record Revenue Amidst Growth ChallengesAugust 1, 2025 | theglobeandmail.comCanaccord Genuity Group Raises Exagen (NASDAQ:XGN) Price Target to $11.00August 1, 2025 | americanbankingnews.comExagen (NASDAQ:XGN) Upgraded at KeyCorpAugust 1, 2025 | americanbankingnews.comCanaccord Genuity Sticks to Its Buy Rating for Exagen (XGN)July 31, 2025 | theglobeandmail.comExagen (NASDAQ:XGN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysJuly 31, 2025 | marketbeat.comExagen (NASDAQ:XGN) Upgraded to "Overweight" at KeyCorpJuly 31, 2025 | marketbeat.comXGN | Exagen Inc. Annual Cash Flow Statement | MarketWatchJuly 31, 2025 | marketwatch.comKeybanc Upgrades Exagen (XGN)July 31, 2025 | msn.comExagen (NASDAQ:XGN) Posts Earnings Results, Hits EstimatesJuly 30, 2025 | marketbeat.comExagen upgraded to Overweight from Sector Weight at KeyBancJuly 30, 2025 | msn.comExagen Q2 Revenue Jumps 14 PercentJuly 29, 2025 | aol.comAExagen Inc. (XGN) Q2 2025 Earnings Call TranscriptJuly 29, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMGL, XGN, DCGO, and SERA Company DescriptionsBasel Medical Group NASDAQ:BMGL$2.06 +0.04 (+1.98%) As of 08/4/2025 04:00 PM EasternBasel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.DocGo NASDAQ:DCGO$1.40 +0.07 (+5.26%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$1.40 0.00 (-0.36%) As of 08/4/2025 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.Sera Prognostics NASDAQ:SERA$2.59 -0.11 (-4.07%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$2.60 +0.02 (+0.58%) As of 08/4/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Exagen NASDAQ:XGN$8.85 +0.22 (+2.55%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$8.85 0.00 (0.00%) As of 08/4/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas How 2 Deals in 48 Hours Changed Everything for Joby Aviation Here's Why Traders Turned Bullish on Boeing Stock Onsemi’s August Pullback Is a Signal to Buy for Tech Investors Strategy Insiders Buy In While Analysts Predict Big Upside Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging Yes, You Can Get Dividends in Tech: 3 Stocks With Yield + Upside MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
